NVO

The article compares Novo Nordisk (NVO) and Viking Therapeutics (VKTX) as investment opportunities in the growing obesity-treatment market projected to reach $114 billion by 2030. NVO has established products like Wegovy and Ozempic but faces intensifying competition from Eli Lilly's tirzepatide drugs.

VKTX, a clinical-stage biotech, is advancing VK2735 in phase III studies with promising maintenance data showing 90% weight-loss retention with biweekly dosing. While NVO offers stability with declining earnings, VKTX presents higher-risk, higher-reward potential with a Zacks Rank #2 (Buy) versus NVO's #3 (Hold).

Novo Nordisk (NVO) closed down 1.06% and has depreciated 10.2% over the past month, underperforming the broader market. The company faces headwinds with projected EPS declining 20.59% for the upcoming quarter and full-year earnings expected to drop 13.64% year-over-year. The stock carries a Zacks Rank #3 (Hold) rating, though it trades at a discount to its industry peers with a Forward P/E of 11.36 versus the industry average of 16.91.

Novo Nordisk (NVO) has underperformed the broader market, declining 10.2% over the past month compared to the S&P 500's 1.5% gain. The company faces earnings headwinds with expected EPS declining 20.6% year-over-year for the current quarter and 13.6% for the fiscal year. However, the stock trades at a valuation discount to peers and maintains a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Novo Nordisk (NVO) closed down 1.35% and has fallen 11.21% over the past month, underperforming the S&P 500. The company is expected to report a 20.59% year-over-year earnings decline with revenue down 3.03%. The stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 11.29, trading at a discount to its industry average, though analyst consensus estimates have moved 3.17% lower in the past month.

Novo Nordisk stock rose 1.95% to $38.26, outperforming a declining market. However, the company faces headwinds with shares down 16.9% over the past month and expected EPS decline of 21.57% in the upcoming quarter.

Revenue is also projected to decline 2.79% year-over-year. The stock holds a Zacks Rank #3 (Hold) rating with a forward P/E of 10.62, trading at a discount to its industry average.

Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating.

Novo Nordisk (NVO) has declined 19.4% over the past month, underperforming the S&P 500. The pharmaceutical company is expected to report lower earnings with a -21.6% year-over-year change for the current quarter, though consensus estimates have improved slightly. Despite recent revenue beats and a favorable valuation grade, the stock carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the broader market.

Novo's COMPETE SWITCH CV study found that patients who escalated their Ozempic dose to 2 mg had a 6% lower observed risk of major adverse cardiovascular events (MACE) compared to those who switched to Eli Lilly's Mounjaro. However, the study shows association rather than causation and did not evaluate safety outcomes.

Novo Nordisk stock declined 1.03% and has fallen 14.6% over the past month, underperforming the broader market. The company faces headwinds with expected EPS down 20.59% and revenue down 2.79% in the upcoming quarter.

However, consensus EPS estimates have shifted upward by 2.49% over the past month, and the stock trades at a discount valuation with a Forward P/E of 10.93 versus industry average of 16.57. The company holds a Zacks Rank of #3 (Hold).

Healthcare sector is experiencing a significant rebound, with ETFs hovering near 52-week highs driven by double-digit earnings growth expectations, positive clinical trial results, attractive valuations, and expanding GLP-1 adoption. Major pharmaceutical companies reported promising drug-trial outcomes in oncology, obesity, and rare diseases, while M&A activity surged to nearly $284 billion. The sector is benefiting from a rotation out of overcrowded AI/tech trades into defensive growth.

Swiss pharma giant Roche Holding AG reported first-nine-month 2026 sales of CHF 46.5 billion, up 6% at constant exchange rates, driven by 7% growth in its Pharmaceuticals division. Five key drugs generated CHF 16.8 billion in sales, up 12% at CER, offsetting declines in legacy products due to loss of exclusivity.

The company reaffirmed mid-single-digit sales growth guidance for 2026 and expects high-single-digit EPS growth. Roche's pipeline includes promising candidates in oncology, immunology, and obesity treatment, with enicepatide showing encouraging phase II results for type 2 diabetes and weight management.

Bristol Myers Squibb has demonstrated more stable and consistent revenue growth over the past two years, leading in seven of eight quarters. Novo Nordisk experienced significant volatility, with a dramatic 32% revenue spike in Q1 2026 following its Wegovy weight-loss pill launch, but faced sequential declines in Q2 2026 due to pricing pressure and ordering patterns. While Novo Nordisk's GLP-1 portfolio drives investor interest, its heavy dependence on Ozempic and Wegovy (70% of sales) presents concentration risk compared to Bristol Myers Squibb's more diversified growth portfolio.

Novo Nordisk, a Denmark-based pharmaceutical leader in diabetes and obesity markets, has faced recent setbacks but could bounce back over the next decade. The company's pipeline includes promising candidates like CagriSema, Amycretin, and UBT251 that could drive growth.

However, patent expirations in 2032, increased competition, and regulatory uncertainties present significant challenges. Despite these risks, the analyst views Novo as an attractive long-term buy with potential for competitive returns, especially with dividend reinvestment.

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR.

North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

Novo Nordisk's Q3 2026 results will focus on Ozempic and Wegovy sales, which represent 75.5% of H1 adjusted sales. The company faces pricing pressure, weaker injectable GLP-1 prescription trends, and intensifying competition from Eli Lilly's tirzepatide drugs. Novo's oral semaglutide pills (Wegovy and Ozempic tablets) show strong early uptake, but overall 2026 guidance remains flat to -6% at constant exchange rates.

Novo Nordisk announced Phase 3 trial results for CagriSema, its next-generation obesity drug combining semaglutide and cagrilintide, showing 25% mean weight loss in women compared to 3% for placebo. While results are competitive with existing treatments like Eli Lilly's Zepbound (26% efficacy), they are not superior enough to significantly recapture market share from Eli Lilly's dominant position. The modest investor reaction suggests the drug alone may not materially improve Novo Nordisk's fortunes, though the company's broader pipeline in other therapeutic areas remains a potential catalyst.

REX Shares launched the REX Peptide ETF (PEPT), offering global exposure to peptide drug developers, manufacturers, and delivery platforms. The fund tracks the VettaFi Peptide Index and charges 65 bps in fees.

With GLP-1 adoption expanding and the global incretin market projected to reach $200 billion by 2030, the peptide market is positioned for significant growth. PEPT competes with similar ETFs THNR and OZEM, which charge 59 bps each.

The MASH (Metabolic Dysfunction-Associated Steatohepatitis) market is rapidly expanding with over 180 companies developing 200+ pipeline therapies. Two drugs have been approved: REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals and LIPAGLYN/BILYPSA (saroglitazar magnesium) by Zydus Lifesciences. The competitive landscape is intensifying with emerging mechanisms of action including FGF21 replacements, GLP-1 receptor agonists, and dual glucagon/GLP-1 agonists, with approximately 5+ drugs in late-stage development and 100+ in mid and early stages.

Prothena Corporation relies on partnerships with major pharmaceutical companies (Roche, Novo Nordisk, and Bristol Myers Squibb) to advance its neurodegenerative and rare disease treatments. The company received a $50M milestone payment for coramitug and estimates $3B in total future milestone payments plus royalties from partnered programs. While partnerships reduce financial burden and provide expertise, they also limit Prothena's control over key programs and expose the company to clinical and commercial risks.

Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth.